UMC
JNCE

UNC Management Company’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

UNC Management Company’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,115
Closed -$55K – 5
2022
Q1 		$55K Buy
+8,115
New +$57.8K 0.02% 5

Other funds holding JNCE

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

UNC Management Company's JNCE Position: Q2 2022 in Review

UNC Management Company sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2022, closing a stake of 8,115 shares — an estimated $55K sold.

UNC Management Company first reported a position in JNCE in Q1 2022 and held it in 1 quarter. The position peaked at $55K in Q1 2022. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.

  • UNC Management Company reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • UNC Management Company sold 8,115 Jounce Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $55K.
  • UNC Management Company first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • UNC Management Company's Jounce Therapeutics, Inc. Common Stock position peaked at $55K in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2022.

Based on UNC Management Company's 13F filing for Q2 2022, filed 12 Aug 2022.